PMID- 37337403
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231216
IS  - 1098-1128 (Electronic)
IS  - 0198-6325 (Linking)
VI  - 44
IP  - 1
DP  - 2024 Jan
TI  - CYP1A inhibitors: Recent progress, current challenges, and future perspectives.
PG  - 169-234
LID - 10.1002/med.21982 [doi]
AB  - Mammalian cytochrome P450 1A (CYP1A) are key phase I xenobiotic-metabolizing 
      enzymes that play a distinctive role in metabolic activation or metabolic 
      clearance of a variety of procarcinogens, drugs, and endogenous substances. Human 
      CYP1A subfamily contains two members (hCYP1A1 and hCYP1A2), which are known to 
      catalyze the oxidative activation of some environmental procarcinogens into 
      carcinogenic species. Increasing evidence has demonstrated that CYP1A inhibitor 
      therapies are promising strategies for cancer chemoprevention or overcoming 
      CYP1A-associated drug toxicity and resistance. Herein, we reviewed recent 
      advances in the discovery and characterization of hCYP1A inhibitors, from the 
      discovery approaches to structural features and biomedical applications of hCYP1A 
      inhibitors. The inhibition potentials, inhibition modes, and inhibition constants 
      of all reported hCYP1A inhibitors are comprehensively summarized. Meanwhile, the 
      structural features and structure-activity relationships of different classes of 
      hCYP1A1 and hCYP1A2 inhibitors are analyzed and discussed in depth. Furthermore, 
      the major challenges and future directions for this field are presented and 
      highlighted. Collectively, the information and knowledge presented here will 
      strongly facilitate the researchers to discover and develop more efficacious 
      CYP1A inhibitors for specific purposes, such as chemo-preventive agents or as 
      tool molecules in hCYP1A-related fundamental studies.
CI  - (c) 2023 Wiley Periodicals LLC.
FAU - Dai, Ziru
AU  - Dai Z
AD  - Key Laboratory of Bioactive Substances and Resources Utilization of Chinese 
      Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Wu, Yue
AU  - Wu Y
AD  - Shanghai Frontiers Science Center for TCM Chemical Biology, Institute of 
      Interdisciplinary Integrative Medicine Research, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Xiong, Yuan
AU  - Xiong Y
AD  - Shanghai Frontiers Science Center for TCM Chemical Biology, Institute of 
      Interdisciplinary Integrative Medicine Research, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Wu, Jingjing
AU  - Wu J
AD  - Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical 
      University, Dalian, China.
FAU - Wang, Min
AU  - Wang M
AD  - Key Laboratory of Bioactive Substances and Resources Utilization of Chinese 
      Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Sun, Xiao
AU  - Sun X
AD  - Key Laboratory of Bioactive Substances and Resources Utilization of Chinese 
      Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Ding, Xinxin
AU  - Ding X
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, University of 
      Arizona, Tucson, America.
FAU - Yang, Ling
AU  - Yang L
AD  - Key Laboratory of Basic Pharmacology of Ministry of Education and Joint 
      International Research Laboratory of Ethnomedicine of Ministry of Education, 
      Zunyi Medical University, Zunyi, China.
FAU - Sun, Xiaobo
AU  - Sun X
AD  - Key Laboratory of Bioactive Substances and Resources Utilization of Chinese 
      Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      China.
FAU - Ge, Guangbo
AU  - Ge G
AD  - Shanghai Frontiers Science Center for TCM Chemical Biology, Institute of 
      Interdisciplinary Integrative Medicine Research, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
LA  - eng
GR  - 81891012/National Natural Science Foundation of China/
GR  - 81803627/National Natural Science Foundation of China/
GR  - 82273897/National Natural Science Foundation of China/
GR  - U20A20405/National Natural Science Foundation of China/
GR  - 81922070/National Natural Science Foundation of China/
GR  - 81973286/National Natural Science Foundation of China/
GR  - 2021-I2M-1-071,2022-I2M-2-001/CAMS Innovation Fund for Medical Sciences/
GR  - 21S21900600/Shanghai Science and Technology Innovation Action Plans/
GR  - 2022CX005/Shanghai Municipal Health Commission's TCM research project/
GR  - ZYYCXTD-D-202004/Innovation Team and Talents Cultivation Program of National 
      Administration of Traditional Chinese Medicine/
PT  - Journal Article
PT  - Review
DEP - 20230619
PL  - United States
TA  - Med Res Rev
JT  - Medicinal research reviews
JID - 8103150
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A2)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Cytochrome P-450 CYP1A1/metabolism
MH  - *Cytochrome P-450 CYP1A2/metabolism
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Mammals/metabolism
OTO - NOTNLM
OT  - CYP1A1
OT  - CYP1A2
OT  - cytochrome P450
OT  - inhibitors
OT  - structure-activity relationships (SARs)
EDAT- 2023/06/20 06:41
MHDA- 2023/12/17 09:43
CRDT- 2023/06/20 01:02
PHST- 2023/03/28 00:00 [revised]
PHST- 2022/12/09 00:00 [received]
PHST- 2023/05/23 00:00 [accepted]
PHST- 2023/12/17 09:43 [medline]
PHST- 2023/06/20 06:41 [pubmed]
PHST- 2023/06/20 01:02 [entrez]
AID - 10.1002/med.21982 [doi]
PST - ppublish
SO  - Med Res Rev. 2024 Jan;44(1):169-234. doi: 10.1002/med.21982. Epub 2023 Jun 19.